Phuong Cao Thi Ngoc is a Postdoctoral Fellow at Lund University , affiliated with the Division of Molecular Hematology (DMH) , RNA and Stem Cell Biology , StemTherapy , and Lund University Cancer Centre (LUCC) . Her research bridges bioinformatics and experimental biology to address hematologic malignancies and regenerative medicine. Current affiliations: Division of Molecular Hematology, LUCC, StemTherapy National Initiative ORCID: 0000-0002-3059-9179 Research hubs: RNA biology, stem cell homeostasis, myeloid disorders Research Interests focus on RNA modifications, hematopoietic stem cell regulation, and leukemogenesis. Key areas include: Mechanistic analysis of tRNA fragmentation in inflammation Epigenetic control of splicing via SF3B1 Redox proteome dynamics during development Role of pseudouridine in protein synthesis fidelity Computational modeling of retrotransposons Translational applications for myelodysplastic syndromes Publication Trends reveal expertise in RNA-related pathologies, computational genomics, and stem cell-driven cancer models. Her recent work spans tRNA modifications, splicing regulation, and fetal tumor suppression mechanisms in myeloid leukemia. Contact : phuong.cao_thi_ngoc@med.lu.se | ORCID
Sarah Rennie serves as Assistant Professor in the Department of Biology within the Faculty of Science at the University of Copenhagen, specializing in Computational and RNA Biology. Her research focuses on RNA modifications and their implications in cancer biology, particularly gastrointestinal and pancreatic cancers. Her primary research interests span RNA modifications, noncoding RNA biology, cancer epigenetics, and bioinformatics. Current work investigates N6-methyladenosine (m6A) modifications in pancreatic cancer progression, tumor microenvironment adaptations, and computational approaches for RNA analysis. Her lab develops and benchmarks bioinformatic tools for lncRNA research and RNA editing detection, bridging wet-lab experiments with computational modeling. Recent publications demonstrate significant contributions to understanding RNA modification roles in cancer, with 2024-2025 work appearing in high-impact journals including Cancer Science , Cell Reports , and EMBO Journal . Her research shows strong emphasis on translational applications, particularly in developing RNA-based cancer biomarkers and therapeutic targets. Rennie serves as Editor for the journal Non-coding RNA (2023), demonstrating leadership in the field. Her work receives consistent attention across academic platforms with multiple mentions on X (formerly Twitter), Reddit, Bluesky, and Mendeley. Her laboratory operates within the Computational and RNA Biology section at Ole Maaløes Vej 5 in Copenhagen, utilizing both experimental and computational approaches to study RNA modifications in disease contexts. Current projects focus on acid microenvironment adaptations in pancreatic cancer and deep learning applications for RNA modification analysis.
Antonio Giraldez is the Fergus F. Wallace Professor of Genetics at Yale School of Medicine, where he has led his research laboratory since 2007. He served as Director of Graduate Studies (2012-2016) and Chair of the Genetics Department (2017-2023). His academic appointments span multiple departments and centers including Biochemistry, Quantitative Biology, Biophysics and Structural Biology (BQBS), the Center for RNA Science and Medicine, Yale Cancer Center, Yale Center for Genomic Health, Yale Combined Program in the Biological and Biomedical Sciences (BBS), and the Yale Stem Cell Center. Professor Giraldez's research focuses on understanding the regulatory code that governs gene expression during vertebrate development after fertilization. His lab investigates four interconnected areas: genome activation during the maternal-to-zygotic transition, post-transcriptional regulation of gene expression, modeling of therapeutic mRNA design, and modeling of gene regulatory networks. Using zebrafish as a primary model organism combined with advanced genomic, computational, and imaging approaches, his lab has made significant contributions to understanding how transcription factors activate the embryonic genome and how RNA regulatory elements control mRNA stability and translation. Analysis of Professor Giraldez's recent publications reveals a strong focus on the molecular mechanisms of embryonic development, particularly the maternal-to-zygotic transition where control of development passes from maternal to embryonic factors. His work increasingly integrates high-throughput genomic approaches with computational modeling to decode regulatory elements in RNA that determine stability, translation efficiency, and tissue-specific expression - knowledge directly applicable to therapeutic mRNA design for gene therapy and vaccines. Scientific Awards and Honors: HHMI Faculty Scholar (2016) Blavatnik Award for Young Scientists National Finalist (2016) Vilcek Prize for Creative Promise in Biomedical Science (2014) Pew Scholar in Biomedical Sciences (2008) NYAS Blavatnik Young Investigator Award Finalist (2007) Professor Giraldez has established a productive research program with consistent funding and publication in top-tier journals. His lab maintains active collaborations with researchers across Yale and beyond, as evidenced by his frequent co-authorship with scientists from multiple departments. He has trained numerous students and postdocs who have gone on to independent research careers. The Giraldez Lab maintains a diverse team of researchers working at the intersection of developmental biology and genomics. The lab provides extensive resources including published datasets, computational tools like CRISPRscan, and detailed genomic annotations available through their data repository. Professor Giraldez's research program continues to advance our understanding of fundamental gene regulatory mechanisms with implications for both basic science and therapeutic applications.
Sigrid Nachtergaele serves as Assistant Professor in the Department of Molecular, Cellular, and Developmental Biology at Yale Graduate School of Arts and Sciences, with cross-appointments across Yale Cancer Center, Center for RNA Science and Medicine, and multiple interdisciplinary programs including Biochemistry/Quantitative Biology (BQBS), Genomics/Genetics/Epigenetics, and the Yale Combined Program in Biological and Biomedical Sciences (BBS). Her research program centers on RNA biology with particular emphasis on epitranscriptomics – investigating how chemical modifications to RNA molecules regulate mRNA function and gene expression. This work combines biochemical methodology development with molecular analysis to understand fundamental regulatory mechanisms, leveraging Yale's specialized resources including the Center for RNA Science and Medicine. Her focus bridges basic molecular mechanisms with potential implications for cancer biology through Yale Cancer Center affiliations. Recent publication trends (2023-2024) demonstrate dual expertise in technical methodology (RT-based mapping of RNA modifications) and conceptual analysis of RNA modification roles in mRNA regulation, alongside contributions to scientific culture discourse. This output appears in high-impact venues including Annual Review of Biochemistry and Methods in Enzymology, reflecting both technical leadership and broad scholarly impact. As an active member of Yale Cancer Center's Genomics, Genetics, and Epigenetics Program, she contributes to collaborative cancer research while mentoring through the BBS graduate program. Her laboratory environment benefits from institutional support through Yale's RNA-focused research infrastructure and cancer center resources, though specific lab branding isn't detailed in available sources.
Toma Tebaldi is an Assistant Professor Adjunct in the Medical Oncology and Hematology department at Yale School of Medicine and a member of the Yale Cancer Center. His interdisciplinary work bridges computational biology and cancer research, with a focus on RNA mechanisms in hematologic malignancies. Dr. Tebaldi maintains affiliations with multiple research programs including Genomics, Genetics, and Epigenetics, and Internal Medicine at Yale. Dr. Tebaldi's educational background includes a PhD in Information and Communication Technology from the University of Trento (2010), an MSc in Biotechnologies - Bioinformatics from University of Milano Bicocca (2006), and a BSc in Biotechnologies from the same institution (2003). His training includes postdoctoral fellowships at University of Trento, EMBO Short Fellowship at University of Edinburgh, and international internships at Harvard Medical School, University of Edinburgh, and University of Sheffield. His research focuses on RNA molecular mechanisms underlying disease dysregulation, combining experimental and computational approaches. Key areas include alternative splicing, non-coding RNA binding, mutant RNA binding proteins, RNA modifications (epitranscriptome), translation dynamics, and single-cell expression data. This work has significant implications for understanding and treating hematologic cancers. Dr. Tebaldi's publication record shows consistent output in high-impact journals from 2022-2025, with research spanning cancer biology, RNA mechanisms, and computational approaches. His work demonstrates increasing sophistication in integrating single-cell technologies with traditional molecular biology techniques to address complex questions in cancer biology. Italian National Scientific Qualification as Associate Professor in Applied Biology (2021) Italian National Scientific Qualification as Associate Professor in Molecular Biology (2020) Yale YCCEH Pilot and Feasibility Program Award (2018) RNA Society Travel Award: RNA2016, Kyoto (2016) EMBO Travel Grant Award: Protein synthesis and translational control (2015) Dr. Tebaldi serves as Associate Editor for Frontiers in Genetics - Computational Biology and as a reviewer for PRIN 2020 MIUR. His membership in the Yale Center for Biomedical Data Science and Yale Cancer Center provides access to extensive collaborative networks and resources. His research program benefits from interdisciplinary connections between computational biology, cancer genomics, and clinical hematology/oncology. Through his Italian Society of Yale Students and Affiliates board membership and Visiting Professor appointments at University of Trento, Dr. Tebaldi maintains strong international connections that enrich his research program and provide opportunities for student exchanges and collaborative projects across continents.
Zongdi Feng is an Assistant Professor of Pediatrics at The Ohio State University and Principal Investigator at the Center for Microbe and Immunity Research within Nationwide Children’s Hospital. He holds a PhD from the University of Illinois (2008) and completed postdoctoral training at UNC-Chapel Hill under Dr. Stan Lemon. His research focuses on hepatitis A and E viruses, with seminal work establishing the 'quasi-enveloped' nature of these pathogens—revealing how they hijack host membranes to evade immune responses and enhance transmission. Research interests center on: Molecular mechanisms of viral entry/release Structural biology of quasi-enveloped virions Virus-antibody interactions Host factors in hepatitis pathogenesis Immunity and vaccine development Recent publications (2021-2024) emphasize hepatitis E virus entry mechanisms, ORF2/ORF3 protein functions, and innovative neutralization assays. Article keywords predominantly span virology , immunology , and cell biology , with subfields including viral membrane trafficking, interferon responses, and host-pathogen coevolution. Laboratory leadership includes directing the Feng Lab at the Center for Microbe and Immunity Research, where projects investigate viral persistence in humanized models and hepatocyte polarization mechanisms.
Martin Jansson is an Assistant Professor at the Biotech Research & Innovation Centre (BRIC) within the Faculty of Health and Medical Sciences at the University of Copenhagen. He leads research in ribosome biology and microRNA regulation in cancer, with a focus on translational control mechanisms and their implications for disease. Dr. Jansson completed his DPhil in Medical Sciences at the University of Oxford in 2008, focusing on the regulation of p53 and the DNA damage response. His academic journey includes postdoctoral research at the University of Copenhagen (2008-2015), research assistant positions at the University of Oxford (2005-2008) and University of Glasgow (2001-2005), and earlier research experience at Queensland University, CSIRO, and Zeneca Pharmaceuticals. His research interests center on ribosome heterogeneity and its impact on translational control, microRNA biology in disease, and the regulation of cell cycle, cellular stress response, apoptosis, and cancer. His work bridges fundamental molecular mechanisms with potential therapeutic applications in oncology. Dr. Jansson's publication record shows a consistent trajectory of high-impact research, with recent articles in Nature Structural & Molecular Biology (2025), Developmental Cell (2023), and Trends in Biochemical Sciences (2022). His work on ribosomal RNA modifications and specialized ribosomes has garnered significant attention, with multiple publications receiving over 100 citations each. His 2023 paper on ribosomal RNA 2'-O-methylation demonstrated how these modifications impact cell fate decisions The 2022 review on translational control through ribosome heterogeneity has been cited over 79 times His foundational 2016 paper on rRNA profiling established evidence for ribosome heterogeneity Dr. Jansson collaborates extensively within the Lund Group at BRIC and with international researchers across multiple disciplines. His work has been featured in news outlets and discussed across social media platforms, indicating broad scientific impact beyond traditional citation metrics. He maintains an active research program investigating how specialized ribosomes contribute to translational control and how dysregulation of these processes leads to cancer and other diseases, with several recent publications continuing to advance this field.
Ferdinand von Walden is an Assistant Professor and Docent at Karolinska Institutet's Department of Women's and Children's Health, where he leads Thomas Sejersen's Neuromuscular Diseases research group. He holds a dual clinical role as a pediatric resident at Astrid Lindgren Children's Hospital. His academic credentials include: Docent (Karolinska Institutet, 2025) PhD in Physiology and Pharmacology (Karolinska Institutet, 2015) Medical Degree (Karolinska Institutet, 2009) Master of Medical Science (Karolinska Institutet, 2007) Dr. von Walden leads multidisciplinary research in muscle physiology with emphases on: Molecular mechanisms of ribosome biogenesis in muscle adaptation Exercise interventions for cerebral palsy patients Epigenetic regulation of muscle growth Systemic effects of endurance/resistance training His work bridges clinical pediatrics with fundamental muscle biology. His publication record demonstrates consistent focus on muscle adaptation mechanisms across populations. Recent work (2022-2025) shows strong trends toward: Advanced molecular analysis of exercise responses Clinical translation in cerebral palsy rehabilitation Innovative biomarker discovery using omics technologies Integration of basic muscle physiology with clinical applications He leads several funded projects including studies on ribosome biogenesis, resistance training in children, and exercise physiology in cerebral palsy. His research team includes 6 PhD students and 2 postdoctoral fellows. He collaborates extensively with Linköping University and has secured significant funding, including a SEK 10 million grant from Promobilia Foundation for research on motor impairments in children.
